Advertisement
Paper| Volume 40, ISSUE 6, P757-767, December 15, 1985

Characterization of human platelet beta-adrenoceptors

DOI:https://doi.org/10.1016/0049-3848(85)90313-5
Characterization of human platelet beta-adrenoceptors
Previous ArticlePurification of glycosylated apoprotein of tissue factor from human brain and inhibition of its procoagulant activity by a specific antibody
Next ArticleThe thrombolytic and hemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabrits
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The widespread use of beta-adrenoceptor antagonists againist hypertension, angina pectoris and migraine or as a preventive treatment after myocardial infarction has encouraged us to investigate the effects of these drugs on platelet function. The aim of this study was to examine whether beta-blocking drugs interfere with platelet beta- adrenoceptors and whether this dependency is related to their selectivity for beta-adrenoceptor subtypes. Beta-adrenoceptor stimulation of human platelets with isoprenaline increased cyclic AMP (cAMP), which is known to inhibit platelet aggregation. Furthermore, our studies showed that cAMP formation Math Eq was stimulated by non-selective and beta2-selective agonists, but not by the predominant beta-agonist prenalterol. Isoprenaline- stimulated cAMP formation was blocked by the non- selective beta-adrenoceptor antagonists propranolol, timolol, and alprenolol, while the betal-selective antagonists atenolol and metoprolol had no influence on an isoprenaline-induced cAMP formation. Receptor binding studies using (3H-dyhydroalprenolol revealed an IC50 value for propranolol of 85 nM, while metoprolol only displaced the bound (33H)-dihydroalprenolol at far higher concentrations (IC50, 20 μM). We conclude that the human platelet beta-adrenoceptors are mainly of the beta2 - subtype and that beta-adrenoceptor antagonists, especially the non-selective antagonists interfere with platelet function assessed as platelet cAMP formation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Lands A.M.
        • Arnold A.
        • McAuliff J.P.
        • Luduena F.P.
        • Brown T.C.
        Differentiation of receptor systems activated by sympathomimetic amines.
        Nature. 1967; 214: 597-598
        • O'Brien J.R.
        Some effects of adrenaline and anti adrenaline compounds on platelets in vitro and in vivo.
        Nature. 1963; 200: 763-764
        • Mills D.C.B.
        • Smith J.B.
        The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3′, 5′-cyclic monophosphate in platelets.
        Biochem. J. 1971; 121: 185-196
        • Mills D.C.B.
        • Smith J.B.
        Control of platelet responsiveness by agents that influence cyclic AMP metabolism.
        Ann. N.Y. Acad. Sci. 1972; 201: 391-399
        • Bygdeman S.
        • Johnson O.
        Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake by noradrenaline and 5-hydroxytryptamine.
        Acta Physiol. Scand. 1969; 75: 128-129
        • Lefkowitz R.J.
        • Mukherjej C.
        • Coverstone M.
        • Caron M.G.
        Stereospecific (3H)-alprenol binding sites, beta-adrenergic receptors and adenyl cyclase.
        Biochem. Biophys. Res. Commun. 1974; 60: 700-709
        • Chung Y.H.
        • Knapp D.R.
        • Halushka P.V.
        The effect of alpha-adrenergic agents on human platelet aggregation.
        J. Pharmacol. Exp. Ther. 1978; 208: 366-370
        • Lasch P.
        • Jakobs K.H.
        Agonistic and antagonistic effects of various alpha-adrenergic agonists in human platelets.
        Naunyn-Schmiedeberg's Archs.Pharmacol. 1979; 306: 119-125
        • Abdulla Y.H.
        Beta-adrenergic receptors in human platelets.
        J. Atheroscler. Res. 1969; 9: 171-177
        • Jakobs K.H.
        • Saur W.
        • Schultz G.
        Characterization of alpha- and beta-adrenergic receptors linked to human platelet adenylate cyclase.
        Naunyn-Schmiedeberg's Archs. Pharmacol. 1978; 302: 285-291
        • Kerry R.
        • Scrutton M.C.
        Platelet beta-adrenoceptors.
        Br. J. Pharmac. 1983; 79: 681-691
        • Hansen K.W.
        • Klysner R.
        • Geisler A.
        • Knudsen J.B.
        • Glaser S.
        • Gormsen J.
        Platelet aggregation and beta-blockers.
        Lancet. 1982; i: 224-225
        • Jurgensen H.J.
        • Dalsgaard-Nielsen j.
        • Kjoller E.
        • Gormsen J.
        Effect of long-term beta-blockade with alprenolol on platelet function and fibrinolytic activity in patients with coronary heart disease.
        Eur. J. Clin. Pharmacol. 1981; 20: 245-250
        • Wang Y.C.
        • Pandey G.N.
        • Mendels J.
        • Frazer A.
        Effect of lithium on prostaglandin El-stimulated adenylate cyclase activity of human platelets.
        Biochem. Pharmacol. 1974; 23: 845-855
        • Geisler A.
        • Klysner R.
        • Thams P.
        • Christensen S.
        A simple and inexpensive protein binding assay for cyclic Af-iP in biological materials.
        Acta pilarmacol. et toxicol. 1977; 40: 356-368
        • Lowry O.H.
        • Rosebrough N.J.
        • Farr A.L.
        • Randall R.J.
        Protein measurements with the folin phenol reagent.
        Biol. Chem. 1951; 193: 265-275
        • Bieth N
        • Rouot B.
        • Schwartz J.
        • Velly J.
        Comparison of pharmacological and binding assays for ten beta-adrenoceptor blocking agents and two beta-adrenoceptor agonists.
        Br. J. Pharmac. 1980; 68: 563-659
        • Hedberg A.
        • Matisson H.
        • Carlsson E.
        Prenalterol, a non-selective beta-adrenoceptor ligand with absolute beta1-selective partial agonist activity.
        J. Pharm. Pharmacol. 1980; 32: 661
        • Dreyer A.C.
        • Offermeyer J.
        In vitro assessment of the selectivities of various beta-adrenergic blocking agents.
        Life Sciences. 1980; 27: 2078-2092
        • Lowgren K.
        • Hedberg A.
        Adrenoceptor blocking agents, compounds related to metoprolol.
        J. Med. Chem. 1981; 24: 451-454
        • Steer M.L.
        • Atlas D.
        Demonstration of human platelet beta-adrenegenic receptors using labelled cyanopindolol and 125I-labelled hydroxybenzylpindolol.
        Biochim. Biophys Acta. 1982; 686: 240-244
        • Kerry R.
        • Scrutton M.C.
        Binding of (3H)-dihydroalprenolol and (3H)-acetobutolol to human blood platelets is not related to occupancy of beta-adrenoceptors.
        Thromb. Res. 1983; 239: 583-594
        • Cambell W.B.
        • Johnson A.R.
        • Callahan K.S.
        • Graham R.M.
        Anti-platelet activity of beta-adrenergic antagonists.
        in: Inhibition of thromboxane synthesis and platelet aggregation in patients receiving long-term propranolol treatment. 5th edition. Lancet. ii. 1981: 1382-1384

      Article info

      Publication history

      Accepted: July 2, 1985
      Received: December 27, 1984

      Identification

      DOI: https://doi.org/10.1016/0049-3848(85)90313-5

      Copyright

      © 1985 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX